Long-term follow-up results of stepwise radical endoscopic resection for Barrett's esophagus with early neoplasia

Kamar Belghazi, Frederike G I van Vilsteren, Bas L A M Weusten, Sybren L Meijer, Jacques J G H M Bergman, Roos E Pouw

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Scopus)


BACKGROUND AND AIMS: Stepwise radical endoscopic resection (SRER) has shown to be effective in eradicating Barrett's esophagus (BE) and its associated dysplasia. The aim of this study was to assess the long-term durability after successful SRER for early Barrett's neoplasia.

METHODS: Patients treated with SRER for BE ≤5 cm with high-grade dysplasia (HGD) or early cancer (EC) and who had reached complete eradication of intestinal metaplasia (CE-IM) and neoplasia (CE-neo) were included. Primary outcomes were recurrence of neoplasia (HGD/EC), recurrence of dysplasia (indefinite for dysplasia included), and recurrence of endoscopically visible BE. Secondary outcomes were buried Barrett's glands, IM in biopsy specimens obtained distal to a normal-appearing neo-squamocolumnar junction (neo-SCJ), need for retreatment, and sustained CE-IM and CE-neo at the last follow-up endoscopy.

RESULTS: Seventy-three patients were included (64 men; mean age, 66 years; median BE, C2M3). Median follow-up was 76 months. Recurrence of neoplasia was observed in 1 patient (T1bN0M0) after 129 months of follow-up and was treated with curative surgery (annual incidence of .22% per patient-year of follow-up). In 4 patients, recurrence of dysplasia was found (.87% per patient-year of follow-up). Twelve patients had recurrent endoscopically visible BE after a median follow-up of 22 months (2.6% per patient-year of follow-up), mostly small islands or tongues. Five patients had a single finding of buried Barrett's glands (1.1% per patient-year of follow-up), and 27 patients (5.9% per patient-year of follow-up) showed IM in biopsy specimens just distal to the neo-SCJ, which was not reproduced in 56%. Retreatment was performed in 9 patients. CE-IM and CE-neo (excluding IM in the neo-SCJ) at the last follow-up endoscopy was seen in 95% and 97% of patients, respectively.

CONCLUSIONS: This study presents the longest published follow-up data on SRER to date. The 6-year outcomes show that successful SRER is a durable treatment for BE ≤5 cm with HGD/EC.

Original languageEnglish
Pages (from-to)77-84
Number of pages8
JournalGastrointestinal Endoscopy
Issue number1
Early online date2017
Publication statusPublished - Jan 2018


  • Adenocarcinoma/pathology
  • Aged
  • Argon Plasma Coagulation
  • Barrett Esophagus/pathology
  • Endoscopy, Digestive System/methods
  • Esophageal Neoplasms/pathology
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Precancerous Conditions/pathology
  • Recurrence
  • Retrospective Studies

Cite this